Last updated on July 2019

A Study of Atezolizumab (Tecentriq) to Investigate Long-term Safety and Efficacy in Previously-treated Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

Brief description of study

This is a Phase III/IV, single-arm, multicenter study of the long-term safety and efficacy of atezolizumab treatment in participants with Stage IIIb or Stage IV NSCLC who have progressed after standard systemic chemotherapy (including if given in combination with anti-programmed cell death protein 1 [anti-PD-1] therapy, after anti-PD-1 as monotherapy, or after tyrosine kinase inhibitor [TKI] therapy). The study will consist of a Screening Period, a Treatment Period, a Treatment Discontinuation Visit, and a Follow-Up Period.

Clinical Study Identifier: NCT03285763

Find a site near you

Start Over

CETUS Hospital Dia

Belo Horizonte, Brazil
  Connect »

Clinica CIMCA

San Jose, Costa Rica
  Connect »


Guatemala, Guatemala
  Connect »

Meander Medisch Centrum

Amersfoort, Netherlands
  Connect »

UMC Radboud Nijmegen

Nijmegen, Netherlands
  Connect »


Zwolle, Netherlands
  Connect »

Mafraq Hospital; Oncology

Abu Dhabi, United Arab Emirates
  Connect »

Tawam Hospital

Al Ain, United Arab Emirates
  Connect »

Mount Vernon Cancer Centre

Northwood, United Kingdom
  Connect »

New Cross Hospital

Wolverhampton, United Kingdom
  Connect »

Mediclinic City Hospital

Dubai, United Arab Emirates
  Connect »

Beijing Hospital

Beijing City, China
  Connect »

Oncologico Potosino

San Luis Potosí, Mexico
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.